W. Jamal

发表

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial

G. Filippatos, S. Pocock, S. Anker, 2021, European journal of heart failure.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

P. Ponikowski, I. Piña, S. Kaul, 2020, The New England journal of medicine.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

G. Filippatos, S. Pocock, S. Anker, 2020, The Lancet.

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

G. Filippatos, S. Anker, J. Butler, 2019, European journal of heart failure.

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction

G. Filippatos, S. Pocock, S. Anker, 2020, Circulation.

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.

P. Ponikowski, G. Filippatos, S. Pocock, 2021, Journal of the American College of Cardiology.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

P. Ponikowski, I. Piña, G. Filippatos, 2020, European journal of heart failure.

Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

G. Filippatos, S. Anker, J. Butler, 2019, European journal of heart failure.

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.

G. Filippatos, S. Pocock, S. Anker, 2021, Journal of the American College of Cardiology.

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

L. Mantovani, A. Turpie, R. Kreutz, 2012, Vascular health and risk management.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

P. Ponikowski, I. Piña, G. Filippatos, 2021, The New England journal of medicine.

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure

G. Filippatos, S. Pocock, S. Anker, 2020, European journal of heart failure.

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.

G. Filippatos, S. Pocock, S. Anker, 2021, Journal of the American College of Cardiology.

Empagliflozin and Major Renal Outcomes in Heart Failure.

G. Filippatos, S. Pocock, S. Anker, 2021, New England Journal of Medicine.

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

P. Ponikowski, G. Filippatos, S. Pocock, 2020, Circulation.

Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

J. Butler, F. Zannad, M. Packer, 2021, Circulation.

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

B. Zinman, S. Pocock, S. Anker, 2020, The lancet. Diabetes & endocrinology.

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

G. Filippatos, S. Pocock, S. Anker, 2021, European heart journal.

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).

G. Lip, D. Fitzmaurice, W. Hacke, 2012, American heart journal.

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

P. Ponikowski, I. Piña, G. Filippatos, 2021, European heart journal.

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.

Akshay S. Desai, P. Ponikowski, G. Filippatos, 2020, European heart journal.

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure

Akshay S. Desai, G. Filippatos, J. Butler, 2019, European journal of heart failure.

A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment

L. Mantovani, A. Turpie, R. Kreutz, 2013, Thrombosis and Haemostasis.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

P. Ponikowski, I. Piña, G. Filippatos, 2020, European Journal of Heart Failure.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

P. Ponikowski, G. Filippatos, M. Senni, 2020, European Journal of Heart Failure.

Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure

J. Butler, M. Packer, M. Brueckmann, 2021, Diabetologie und Stoffwechsel.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

P. Ponikowski, I. Piña, S. Kaul, 2020, New England Journal of Medicine.